Wellness-focused holding company, Onassis Holdings Corp (OTCMKTS:ONSS) on May 3, 2023, announced a foray into the rejuvenation therapy market with ground-breaking epigenetic programming technology. Onassis has an exclusive perpetual licensing agreement with a leading Israeli university. This will enable it to develop, manufacture, market as well as sell products harnessing cutting-edge technology globally.
On Wednesday, ONSS stock ended flat at $0.0330 with more than 29.72K shares traded, compared to volume of 1.25K shares. The stock moved within a range of $0.0330 – 0.0330 after opening trading at $0.0520.
Onassis Holdings Enters the Rejuvenation Therapy Race with Innovative Epigenetic Programming
The company has been engaged in dedicated research for years leading to the development of advanced epigenetic editing techniques. The technology has the potential to reset the epigenetic clock in aged cells, restoring cells to their youthful state and reversing the loss of functional activity.
The technique harnesses specialized to make targeted changes to chemical marks on DNA influencing gene activity. The accumulating marks lead to loss of function and the development of age-related diseases. Selective modification of marks through epigenetic editing can bring alive cells and turn back the clock on aging, ameliorating holistic health.
Targeting Age-Related Diseases with this technology not only reverses the aging process but also provides a cure against cure specific age-related diseases, like Alzheimer’s, Parkinson’s, and age-related macular degeneration amongst others.The technology addresses the root cause of various conditions, through restoration of proper function and rejuvenating aged cells, leading to healthier and longer lives.